CSF_PsA_Highlights Brochure_ACR2022
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Chairman’s Picks<br />
2136<br />
2137<br />
2138<br />
2139<br />
2141<br />
2142<br />
Deucravacitinib, an Oral, Selective Tyrosine Kinase<br />
2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis:<br />
Achievement of Minimal Disease Activity and Its<br />
Components<br />
Arthur Kavanaugh<br />
Impact of Patient Characteristics, Including Sex,<br />
on the Efficacy of Upadacitinib Compared with<br />
Adalimumab in Patients with Psoriatic Arthritis<br />
Lihi Eder<br />
Real-world Persistence and Treatment Patterns in<br />
Psoriatic Arthritis Patients Treated with Anti-IL17<br />
Therapy<br />
Sebastian Moyano<br />
Sustained Response to Guselkumab Regardless of<br />
Baseline Demographic, Disease, and Medication<br />
Characteristics in Patients with Active Psoriatic<br />
Arthritis and an Inadequate Response to TNF<br />
Inhibitors: Results from a Phase 3b Trial<br />
Iain B McInnes<br />
How Well Does Ultrasound-assessed Synovitis<br />
in Reduced Joint Sets Predict the Response to<br />
Secukinumab in Patients with Active Psoriatic Arthritis<br />
and Inadequate Response to Conventional DMARDs?<br />
– Exploratory Results from a Phase 3b Study<br />
Maria-Antonietta D’Agostino<br />
Strong Correlation Between Short- vs Long-form<br />
Composite Measures of Psoriatic Arthritis Disease<br />
Activity in a TNFi-IR Population Treated with<br />
Guselkumab: Data from the Phase 3b COSMOS Trial<br />
William Tillett<br />
2146<br />
2149<br />
2150<br />
2151<br />
09:15–<br />
09:25<br />
L02<br />
Efficacy of Upadacitinib in Patients with Psoriatic<br />
Arthritis and Prior Exposure to Anti-TNF Therapy in<br />
the SELECT-<strong>PsA</strong> 2 Trial Through 2 Years<br />
Philip J Mease<br />
Cycling versus Swapping Strategies in Psoriatic<br />
Arthritis: Results from the Rheumatic Diseases<br />
Portuguese Register<br />
Francisca Guimarães<br />
Cycling vs Swapping Strategies with TNFi and IL-17i<br />
in Psoriatic Arthritis: An Observational Retrospective<br />
Monocentric Study<br />
Carlo Salvarani<br />
Izokibep Demonstrates Clinically Relevant Efficacy<br />
Benefits on Enthesitis, Dactylitis and Nail Outcomes<br />
in Active <strong>PsA</strong> Patients: A 16-week Randomized,<br />
Placebo-controlled Trial<br />
Kurt de Vlam<br />
ORAL SESSION<br />
LATE-BREAKING ABSTRACTS (L01–L06)<br />
Bimekizumab Treatment in Biologic DMARD-Naïve<br />
Patients with Active Psoriatic Arthritis: 52-Week<br />
Efficacy and Safety Results from a Phase 3,<br />
Randomized, Placebo-Controlled, Active Reference<br />
Study<br />
Christopher T. Ritchlin<br />
2143<br />
Effect of Upadacitinib and Adalimumab on Residual<br />
Pain Among Patients with Psoriatic Arthritis Whose<br />
Inflammation Was Attenuated After Three and Six<br />
Months of Treatment<br />
Louis Bessette<br />
2145<br />
Efficacy and Safety of Risankizumab for Active<br />
Psoriatic Arthritis: 100-Week Results from the<br />
KEE<strong>PsA</strong>KE 1 and KEE<strong>PsA</strong>KE 2 Trials<br />
Lars Erik<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Change language